Top

14-08-2017 | Giant cell arteritis | Review | Article

Giant Cell Arteritis: Current and Future Treatment Options

Journal: Current Treatment Options in Rheumatology

Authors: Gregory McDermott, Eli Miloslavsky

Publisher: Springer International Publishing

Abstract

Giant cell arteritis (GCA) is the most common vasculitis affecting patients over the age of 50. Glucocorticoids have been the mainstay of GCA treatment for nearly 70 years. While prompt treatment with prednisone at a dose of at least 40 mg is effective in preventing severe ischemic complications such as visual loss, frequent relapses and treatment-related morbidity remain significant challenges. New insights into disease pathogenesis have led to recent approval of tocilizumab for the treatment of GCA in conjunction with prednisone. While tocilizumab was studied in patients with new-onset disease, it is not yet clear whether it will be used routinely as initial therapy or will be primarily used in patients with relapsing disease or those intolerant to glucocorticoids. Prior to tocilizumab approval, methotrexate was the first-line steroidsparing agent and will likely continue to have a role in the treatment of GCA due to its modest steroidsparing effect. Other biologics such as abatacept and ustekinumab may have efficacy in GCA but require further study. Experience with cyclophosphamide, azathioprine, leflunomide, and mycophenolate mofetil is limited to small studies and their efficacy in GCA is uncertain. The use of intravenous glucocorticoids for patients with ocular symptoms and duration of glucocorticoid therapy in patients with GCA also require further study. Aspirin may help prevent ischemic complications in GCA; however, prospective studies of this agent are lacking.

Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. Solomon CG, ed. N Engl J Med. 2014; 371(1):50–57. doi:10.1056/NEJMcp1214825.

Weyand CM, Goronzy JJ. Immune mechanisms in medium and large-vessel vasculitis. Nat Rev Rheumatol. 2013;9(12):731–40. doi:10.1038/nrrheum.2013.161.CrossRefPubMedPubMedCentral

Dasgupta B, Panayi GS. Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol. 1990;29(6):456–8.CrossRefPubMed

Loock J, Henes J, Kötter I, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol. 30(1 Suppl 70):S70–6.

Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121(7):906–15. doi:10.1161/CIRCULATIONAHA.109.872903.CrossRefPubMedPubMedCentral

Nuenninghoff DM, Hunder GG, Christianson TJH, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48(12):3522–31. doi:10.1002/art.11353.CrossRefPubMed

García-Martínez A, Hernández-Rodríguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum. 2008;59(3):422–30. doi:10.1002/art.23315.CrossRefPubMed

Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis. 2013;72(12):1989–94. doi:10.1136/annrheumdis-2012-202408.CrossRefPubMed

• Buttgereit F, Dejaco C, Matteson EL, Dasgupta B, JWB BF-G. Polymyalgia rheumatica and giant cell arteritis. JAMA. 2016;315(22):2442. doi:10.1001/jama.2016.5444. Systematic review of diagnosis and treatment of polymyalgia rheumatica and giant cell arteritis. Highlights use of glucocorticoids for GCA treatment

10.

• Labarca C, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology. 2016;55(2):347–56. doi:10.1093/rheumatology/kev348. Retrospective cohort study of patients with giant cell arteritis. Includes analysis of patients that achieved successful glucocorticoid tapering as well as treatment-related side effects

11.

Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989;48(8):658–61.CrossRefPubMedPubMedCentral

12.

• Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–23. doi:10.1136/ard.2008.088351. EULAR guidelines for management of large vessel vasculitis. Includes recommendations for steroid treatment and taper as well as disease monitoring

13.

Dasgupta B, Borg FA, Hassan N, et al. Guidelines BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatol. 2010;49:1594–7. doi:10.1093/rheumatology/keq039a.CrossRef

14.

González-Gay MA, Blanco R, Rodríguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 1998;41(8):1497–504. doi:10.1002/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z.CrossRefPubMed

15.

Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54(10):3310–8. doi:10.1002/art.22163.CrossRefPubMed

16.

Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol. 2000;27(6):1484–91.PubMed

17.

Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand. 2002;80(4):355–67.CrossRefPubMed

18.

Chan CC, Paine M, O’Day J. Steroid management in giant cell arteritis. Br J Ophthalmol. 2001;85(9):1061–4.CrossRefPubMedPubMedCentral

19.

Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003;110(3):539–42. doi:10.1016/S0161-6420(02)01775-X.CrossRefPubMed

20.

• Stone J, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab for giant cell arteritis. N Engl J Med. 2017;(in press). Phase III clinical trial of tocilizumab for treatment of giant cell arteritis. The study showed improved relapse-free survival in the group using tocilizumab plus glucocorticoids compared to patients treated with a 12-month course of prednisone and placebo.

21.

Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis. Medicine (Baltimore). 2011;90(3):186–93. doi:10.1097/MD.0b013e31821c4fad.CrossRef

22.

Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703–8. doi:10.1002/art.11388.CrossRefPubMed

23.

Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26. doi:10.1002/acr.20295.CrossRefPubMed

24.

Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735–40.CrossRefPubMed

25.

Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: a case series. Arthritis Care Res (Hoboken). 2011;63(5):761–5. doi:10.1002/acr.20435.CrossRefPubMedPubMedCentral

26.

Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum. 2001;44(12):2933–5.CrossRefPubMed

27.

Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146(9):621–30.CrossRefPubMed

28.

Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis. 2008;67(5):625–30. doi:10.1136/ard.2007.082115.CrossRefPubMed

29.

Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73(12):2074–81. doi:10.1136/annrheumdis-2013-203586.CrossRefPubMed

30.

Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series Swiss Med Wkly. 2011;141:w13156. doi:10.4414/smw.2011.13156.PubMed

31.

Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken). 2012;64(11):1720–9. doi:10.1002/acr.21750.CrossRefPubMed

32.

Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–7. doi:10.1016/S0140-6736(16)00560-2.CrossRefPubMed

33.

Unizony SH, Dasgupta B, Fisheleva E, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013;2013:1–10. doi:10.1155/2013/912562.CrossRef

34.

Efficacy and safety study of sirukumab in patients with giant cell arteritis. https://clinicaltrials.gov/ct2/show/NCT02531633. Accessed January 1, 2017.

35.

Vital EM, Emery P. Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2006;2(4):365–75.CrossRefPubMedPubMedCentral

36.

Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven R, Malmström V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14(1):34. doi:10.1186/1471-2172-14-34.CrossRefPubMedPubMedCentral

37.

• Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69(4):837–45. doi:10.1002/art.40044. Multicenter trial of the use of abatacept in addition to glucocorticoids for the treatment of giant cell arteritis. The study demonstrated an increase in relapse-free survival at 12 months with abatacept when compared to prednisone alone

38.

Langford CA, Cuthbertson D, Ytterberg SR, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Takayasu arteritis. Arthritis Rheumatol (Hoboken, NJ). 2017;69(4):846–53. doi:10.1002/art.40037.CrossRef

39.

Quatresooz P, Hermanns-Lê T, Piérard GE, Humbert P, Delvenne P, Piérard-Franchimont C. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: a primer. J Biomed Biotechnol. 2012;2012:147413. doi:10.1155/2012/147413.CrossRefPubMedPubMedCentral

40.

Conway R, O'Neill L, O’flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis. 2016;7575(8):1578–9. doi:10.1136/annrheumdis-2016-209351.CrossRef

41.

Ustekinumab for the treatment of giant cell arteritis (UGCA). https://clinicaltrials.gov/ct2/show/NCT02955147. Accessed January 1, 2017.

42.

Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19(5):495–501.PubMed

43.

Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46(5):1309–18. doi:10.1002/art.10262.CrossRefPubMed

44.

Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134(2):106–14.CrossRefPubMed

45.

Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–97. doi:10.1002/art.22754.CrossRefPubMed

46.

Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology. 2012;51(9):1677–86. doi:10.1093/rheumatology/kes127.CrossRefPubMed

47.

de Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013;43(1):105–12. doi:10.1016/j.semarthrit.2012.12.023.CrossRefPubMed

48.

Sailler L, Lapeyre-Mestre M, Geffray L, Letellier P, Liozon E, de La Roque P. Adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis: a double blind randomized controlled trial [abstract]. Arthritis Rheum. 2009;60(Suppl 10):1972.

49.

De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis. 1986;45(2):136–8.CrossRefPubMedPubMedCentral

50.

Liozon F, Vidal E, Barrier J. Does dapsone have a role in the treatment of temporal arteritis with regard to efficacy and toxicity? Clin Exp Rheumatol. 1993;11(6):694–5.PubMed

51.

Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66(9):906–9. doi:10.1111/j.1742-1241.2012.02981.x.CrossRefPubMed

52.

Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:1–3. doi:10.1155/2013/120638.CrossRef

53.

Sciascia S, Piras D, Baldovino S, et al. Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin Exp Res. 2012;24(3):273–7.CrossRefPubMed

54.

Hartmann B, Mohan S V, Goronzy JJ, Weyand CM. Abstract 14947: JAK/STAT-signaling in giant cell arteritis. Circulation. 2016; 128 (Suppl 22).

55.

Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50(4):1332–7. doi:10.1002/art.20171.CrossRefPubMed

56.

Narváez J, Bernad B, Gómez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008;26(3 Suppl 49):S57–62.PubMed

57.

Berger CT, Wolbers M, Meyer P, Daikeler T, Hess C. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology. 2008;48(3):258–61. doi:10.1093/rheumatology/ken480.CrossRef

58.

Salvarani C, Bella CD, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology. 2008;48(3):250–3. doi:10.1093/rheumatology/ken465.CrossRefPubMed

59.

Martínez-Taboada VM, López-Hoyos M, Narvaez J, Muñoz-Cacho P. Effect of antiplatelet/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev. 2014;13(8):788–94. doi:10.1016/j.autrev.2014.02.006.CrossRefPubMed

60.

Meroni PL, Luzzana C, Ventura D. Anti-inflammatory and immunomodulating properties of statins: an additional tool for the therapeutic approach of systemic autoimmune diseases? Clin Rev Allergy Immunol. 2002;23(3):263–78. doi:10.1385/CRIAI:23:3:263.CrossRefPubMed

61.

Pugnet G, Sailler L, Bourrel R, Montastruc J-L, Lapeyre-Mestre M. Is statin exposure associated with occurrence or better outcome in giant cell arteritis? Results from a French population-based study. J Rheumatol. 2015;42(2):316–22. doi:10.3899/jrheum.140906.CrossRefPubMed

62.

Schmidt J, Kermani TA, Muratore F, Crowson CS, Matteson EL, Warrington KJ. Statin use in giant cell arteritis: a retrospective study. J Rheumatol. 2013;40(6):910–5. doi:10.3899/jrheum.121150.CrossRefPubMedPubMedCentral

63.

García-Martínez A, Hernández-Rodríguez J, Grau JM, Cid MC. Treatment with statins does not exhibit a clinically relevant corticosteroid-sparing effect in patients with giant cell arteritis. Arthritis Rheum. 2004;51(4):674–8. doi:10.1002/art.20541.CrossRefPubMed

64.

Narvaez J, Bernad B, Nolla JM, Valverde J. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum. 2007;36(5):322–7. doi:10.1016/j.semarthrit.2006.10.001.CrossRefPubMed

65.

Nagel MA, White T, Khmeleva N, et al. Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis. JAMA Neurol. 2015;72(11):1281. doi:10.1001/jamaneurol.2015.2101.CrossRefPubMedPubMedCentral

66.

67.

Miloslavsky EM, Naden RP, Bijlsma JWJ, et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543–6. doi:10.1136/annrheumdis-2016-210002.CrossRefPubMed

68.

Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. April 2017:ASN.2016111179. doi:10.1681/ASN.2016111179.

Medicine Matters Rheumatology

Abstract